| 2016 | | Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer | 노오규, 박래웅, 박성용, 안미선, 오영택, 윤덕용, 이현우, 전미선, 최진혁, 허재성 |
| 2023 | | Radioimmunotherapy with 131I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma | 정성현 |
| 2015 | | Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. | 이현우 |
| 2019 | | Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer | 최진혁 |
| 2023 | | Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation | 박준성 |
| 2019 | | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial | 강석윤 |
| 2016 | | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF | 박준성 |
| 2012 | | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial | 박준성 |
| 2006 | | The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis. | 강승희, 김효철, 박광주, 박준성, 신승수, 오영택, 오윤정, 이현우, 전미선, 최진혁, 황성철 |
| 2011 | | Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. | 박준성 |
| 2014 | | Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. | 강두경, 강석윤, 김구상, 김태희, 안영실, 임현이, 정용식 |
| 2017 | | Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer | 김진홍, 양민재, 유병무, 이현우, 황재철 |
